|
Facebook
Twitter
Linkedin
|
Acceleware's multi-core image reconstruction solution adopted by major pharmaceutical company
| Company News - Acceleware Corporation |
Acceleware Corp. (TSX-V: AXE), a leading developer of high-performance computing applications, today announced the adoption of the AxRecon image reconstruction solution for micro-computed tomography (CT) by a major pharmaceutical company. Eli Lilly, a leading developer of pharmaceutical products, has selected AxRecon™ solution to speed up image reconstruction times used Acceleware Corp. in the pharmaceutical development process.
"Our early success in helping pharmaceutical companies reduce time spent in drug development is encouraging," said Sean Krakiwsky, CEO of Acceleware Corp. "AxRecon's ability to simply and seamlessly fit with existing CT scanner hardware and software to deliver results up to 50 times faster makes our product attractive to medical researchers and other users of CT Scanners."
Pharmaceutical researchers regularly use CT scanners in the drug development process to observe the effects of novel drug candidates on anatomy. However, deriving value from CT scanners for drug development is hampered by slow image reconstruction time due to insufficient computing power. This reduces efficiency as well as the researcher's ability to maximize the capabilities of advanced imaging equipment. Acceleware Corp.'s solution eliminates the computer processing bottleneck in image reconstruction workflow, and speeds up the evaluation of drug effectiveness.
Acceleware Corp.'s AxRecon works as a turn-key solution with a low cost of operation that fits into the current CT Scanner workflow, generating fully reconstructed, quality images completed hours sooner than before.
Acceleware Corp.'s application acceleration platform utilizes the power of NVIDIA® Graphic Processing Units (GPUs) to dramatically increase the speed of sophisticated computations, saving on power and space while maintaining image quality.











